Dynamics of sequencing of cyclin-dependent kinase inhibitors and cost expenditure analysis in the management of metastatic hormone-receptor positive, human epidermal growth factor 2-negative advancedbreast cancer
Saved in:
| Main Authors: | Amol Patel, T VSGK Tilak, Vineet G Gupta, Atul Batra, Prashant Mehta, Purvish Parikh, Hemant Malhotra |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2019-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=2;spage=311;epage=313;aulast= |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trastuzumab emtansine for residual invasive human epidermal growth receptor-2-positive breast cancer
by: Joydeep Ghosh, et al.
Published: (2020-01-01) -
Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors
by: E. V. Artamonova, et al.
Published: (2019-09-01) -
Commentary on oncotype Dx
by: Prashant Mehta, et al.
Published: (2019-01-01) -
CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB – A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCER
by: E. N. Imyanitov, et al.
Published: (2017-12-01) -
Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC)
by: Purvish M. Parikh, et al.
Published: (2025-01-01)